Compare IRDM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRDM | PTGX |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.4B |
| IPO Year | 2007 | 2016 |
| Metric | IRDM | PTGX |
|---|---|---|
| Price | $52.74 | $130.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $29.80 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 3.5M | 727.2K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 12.77 | N/A |
| EPS | ★ 0.20 | 0.05 |
| Revenue | ★ $871,659,000.00 | N/A |
| Revenue This Year | $3.18 | $874.25 |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | ★ $268.75 | $2,632.40 |
| Revenue Growth | ★ 4.93 | N/A |
| 52 Week Low | $15.65 | $50.49 |
| 52 Week High | $57.18 | $131.87 |
| Indicator | IRDM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 75.18 |
| Support Level | $17.20 | $94.48 |
| Resistance Level | $53.83 | N/A |
| Average True Range (ATR) | 2.99 | 4.88 |
| MACD | 0.88 | 1.40 |
| Stochastic Oscillator | 73.22 | 88.64 |
Iridium Communications Inc is the commercial provider of communications services offering true globalised coverage, connecting people, organizations, and assets to and from anywhere, in real time. The company is a provider of mobile voice and data communications services through a constellation of low-earth-orbiting satellites. Iridium's solutions are ideally suited for industries such as maritime, aviation, government/military, emergency/humanitarian services, mining, forestry, oil and gas, heavy equipment, transportation, and utilities. Iridium also provides service to subscribers from the U.S. Department of Defense, as well as other civil and government agencies world-wide. The Company operates in one business segment, providing satellite communications services and products.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.